{
  "source": "PA-Med-Nec-Qfitlia.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2372-1\nProgram Prior Authorization/Medical Necessity\nMedication Qfitlia® (fitusiran)\nP&T Approval Date 5/2025\nEffective Date 7/1/2025\n1. Background:\nQfitlia (fitusiran) is an antithrombin-directed small interfering ribonucleic acid indicated for\nroutine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric\npatients aged 12 years and older with hemophilia A or B with or without factor VIII or IX\ninhibitors.\n2. Coverage Criteriaa:\nA. Hemophilia A With Inhibitors\n1. Initial Authorization\na. Qfitlia will be approved based on all of the following criteria\n(1) Diagnosis of hemophilia A\n-AND-\n(2) Patient has developed high-titer factor VIII inhibitors ( > 5 Bethesda units [BU])\n-AND-\n(3) Patient is 12 years of age or older\n-AND-\n(4) Prescribed for the prevention of bleeding episodes (i.e., routine prophylaxis)\nAuthorization of therapy will be issued for 12 months.\n2. Reauthorization\na. Documentation of positive clinical response to Qfitlia therapy\nAuthorization will be issued for 12 months.\nB. Hemophilia A Without Inhibitors\n1. Initial Authorization\n© 2025 UnitedHealthcare Services Inc.\n1\na. Qfitlia will be approved based on all of the following criteria\n(1) One of the following:\n(a) Both of the following:\ni. Diagnosis of severe hemophilia A\n-AND-\nii. Documentation of endogenous factor VIII levels less than 1% of normal\nfactor VIII (< 0.01 IU/mL)\n-OR-\n(b) Both of the following:\ni. One of the following\n1. Both of the following\na. Diagnosis of moderate hemophilia A\n-AND-\nb. Documentation of endogenous factor VIII level >1% < 5% (greater\nthan or equal to 0.01 IU/mL to less than 0.05 IU/mL)\n-OR-\n2. Both of the following\na. Diagnosis of mild hemophilia A\n-AND-\nb. Documentation of endogenous factor VIII level > 5% (greater than\nor equal to 0.05 IU/mL)\n-AND-\nii. Submission of medical records (e.g., chart notes, laboratory values)\ndocumenting a failure to meet clinical g",
    "ation of endogenous factor VIII level > 5% (greater than\nor equal to 0.05 IU/mL)\n-AND-\nii. Submission of medical records (e.g., chart notes, laboratory values)\ndocumenting a failure to meet clinical goals (e.g., continuation of\nspontaneous bleeds, inability to achieve appropriate trough level, previous\nhistory of inhibitors) after a trial of prophylactic factor VIII replacement\nproducts\n-OR-\n(c) All of the following:\n© 2025 UnitedHealthcare Services Inc.\n2\ni. Patient is currently on Qfitlia therapy\n-AND-\nii. Diagnosis of hemophilia A\n-AND-\niii. Patient has not received a manufacturer supplied sample at no cost in\nprescriber office, or any form of assistance from the HemAssist or Sanofi\nPatient Support (e.g., sample card which can be redeemed at a pharmacy\nfor a free supply of medication) as a means to establish as a current user of\nQfitlia*\n-AND-\n(2) Patient is 12 years of age or older\n-AND-\n(3) Qfitlia is prescribed for the prevention of bleeding episodes (i.e., routine\nprophylaxis)\n* Patients requesting initial authorization who were established on therapy via the receipt of a\nmanufacturer supplied sample at no cost in the prescriber’s office or any form of assistance from\nthe HemAssist or Sanofi Patient Support shall be required to meet initial authorization criteria as\nif patient were new to therapy.\nAuthorization of therapy will be issued for 12 months.\n2. Reauthorization\na. Qfitlia will be approved based on the following criterion:\n(1) Documentation of positive clinical response to Qfitlia therapy\nAuthorization will be issued for 12 months.\nC. Hemophilia B With Inhibitors\n1. Initial Authorization\na. Qfitlia will be approved based on all of the following criteria\n(1) Diagnosis of hemophilia B\n-AND-\n(2) Patient has developed high-titer factor IX inhibitors ( > 5 Bethesda units [BU])\n© 2025 UnitedHealthcare Services Inc.\n3\n-AND-\n(3) Patient is 12 years of age or older\n-AND-\n(4) Prescribed for the prevention of bleeding episodes (i.e., routine prophylaxis)\nAuthori",
    "hesda units [BU])\n© 2025 UnitedHealthcare Services Inc.\n3\n-AND-\n(3) Patient is 12 years of age or older\n-AND-\n(4) Prescribed for the prevention of bleeding episodes (i.e., routine prophylaxis)\nAuthorization of therapy will be issued for 12 months.\n2. Reauthorization\na. Documentation of positive clinical response to Qfitlia therapy\nAuthorization will be issued for 12 months.\nD. Hemophilia B Without Inhibitors\n1. Initial Authorization\na. Qfitlia will be approved based on all of the following criteria\n(1) One of the following:\n(a) Both of the following:\ni. Diagnosis of severe hemophilia B\n-AND-\nii. Documentation of endogenous factor IX levels less than 1% of normal\nfactor IX (< 0.01 IU/mL)\n-OR-\n(b) Both of the following:\ni. One of the following\n1. Both of the following\na. Diagnosis of moderate hemophilia B\n-AND-\nb. Documentation of endogenous factor IX level >1% < 5% (greater\nthan or equal to 0.01 IU/mL to less than 0.05 IU/mL)\n-OR-\n© 2025 UnitedHealthcare Services Inc.\n4\n2. Both of the following\na. Diagnosis of mild hemophilia B\n-AND-\nb. Documentation of endogenous factor IX level > 5% (greater than or\nequal to 0.05 IU/mL)\n-AND-\nii. Submission of medical records (e.g., chart notes, laboratory values)\ndocumenting a failure to meet clinical goals (e.g., continuation of\nspontaneous bleeds, inability to achieve appropriate trough level, previous\nhistory of inhibitors) after a trial of prophylactic factor IX replacement\nproducts\n-OR-\n(c) All of the following:\ni. Patient is currently on Qfitlia therapy\n-AND-\nii. Diagnosis of hemophilia B\n-AND-\niii. Patient has not received a manufacturer supplied sample at no cost in\nprescriber office, or any form of assistance from the HemAssist or Sanofi\nPatient Support (e.g., sample card which can be redeemed at a pharmacy\nfor a free supply of medication) as a means to establish as a current user of\nQfitlia*\n-AND-\n(2) Patient is 12 years of age or older\n-AND-\n(3) Qfitlia is prescribed for the prevention of bleeding episodes (i.e., routin",
    "of medication) as a means to establish as a current user of\nQfitlia*\n-AND-\n(2) Patient is 12 years of age or older\n-AND-\n(3) Qfitlia is prescribed for the prevention of bleeding episodes (i.e., routine\nprophylaxis)\n* Patients requesting initial authorization who were established on therapy via the receipt of a\nmanufacturer supplied sample at no cost in the prescriber’s office or any form of assistance from\nthe HemAssist or Sanofi Patient Support shall be required to meet initial authorization criteria as\nif patient were new to therapy.\n© 2025 UnitedHealthcare Services Inc.\n5\nAuthorization of therapy will be issued for 12 months.\n2. Reauthorization\na. Qfitlia will be approved based on the following criterion:\n(1) Documentation of positive clinical response to Qfitlia therapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n4. References:\n1. Qfitlia® [package insert]. Cambridge, MA: Genzyme Corporation; March 2025.\n2. Young G, Srivastava A, Kavakli K, et al. Efficacy and safety of fitusiran prophylaxis in people\nwith haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label,\nrandomised phase 3 trial. Lancet. 2023;401(10386):1427-1437. doi:10.1016/S0140-\n6736(23)00284-2\n3. Srivastava A, Rangarajan S, Kavakli K, et al. Fitusiran prophylaxis in people with severe\nhaemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label,\nrandomised, phase 3 trial. Lancet Haematol. 2023;10(5):e322-e332. doi:10.1016/S2352-\n",
    "is in people with severe\nhaemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label,\nrandomised, phase 3 trial. Lancet Haematol. 2023;10(5):e322-e332. doi:10.1016/S2352-\n3026(23)00037-6\nProgram Prior Authorization/Medical Necessity - Qfitlia (fitusiran)\nChange Control\n5/2025 New program\n© 2025 UnitedHealthcare Services Inc.\n6"
  ]
}